Pfizer and Merck team up to work on anti-cancer treatment

Pfizer and Merck team up to work on anti-cancer treatment
Text size Aa Aa

The pharmaceutical companies Merck and Pfizer have signed a deal to develop and market immunology drugs that target cancer.

The two are developing a type of treatment that works by using a patient’s immune system to fight malignant cells more effectively.

Pfizer will pay $850m to gain access and share rights to Merck’s experimental immunology drug, known as anti-PD-L1 therapies. Merck is also in line to receive up to $2bn in payments based on the future success of the treatment.
The experimental drug works by blocking a tumour’s ability to sidestep the body’s immune system.

“It is the largest deal in the pharmaceutical industry for a single asset in this stage of development,” said Belén Garijo, chief executive of Merck’s pharmaceutical division.
The two also plan to work together on Pfizer’s anti-PD-1 antibody, another anti-cancer drug. Merck, in turn, will help to promote Pfizer’s lung cancer drug Xalkori in the US and other markets.

Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.